Group 1 - The 2025 Guangdong Urology Academic Conference and Bladder Cancer Academic Conference successfully concluded in Shenzhen, showcasing the innovative UriFind® product from Benchmark Medical [1] - The product demonstrated significant results in early screening and diagnosis of urothelial carcinoma, with a sensitivity of 89.74%, specificity of 92.46%, and accuracy of 91.47% based on a clinical study involving 1,172 samples [1] - UriFind® provides comprehensive assessment for bladder cancer, renal pelvis cancer, and ureteral cancer, particularly excelling in detecting early, small, residual, and recurrent bladder cancer [1] Group 2 - Benchmark Medical, a subsidiary of Kangsheng Global Medical Testing Group, focuses on cancer early diagnosis and screening using tumor DNA methylation sequencing technology [5] - The company has developed products targeting over 70% of high-incidence cancers, including lung cancer, breast cancer, digestive system cancers, and urinary system cancers, covering the entire process from early screening to monitoring and companion diagnosis [5] - Benchmark Medical has also established a big data and artificial intelligence platform centered on early screening, diagnosis, and treatment of lung cancer [5]

Group 1 - The 2025 Guangdong Urology Academic Conference and Bladder Cancer Academic Conference was successfully held in Shenzhen from August 15-17, 2025, showcasing advancements in early screening for tumors [1] - The UriFind® product by Benchmark Medical was highlighted as an innovative leader in the field of early screening for urinary tract cancers, receiving significant attention from experts [1] - Clinical research involving 1,172 samples demonstrated that the UriFind® kit has a sensitivity of 89.74%, specificity of 92.46%, and accuracy of 91.47% for assisting in the diagnosis of urinary tract cancers [1] Group 2 - Benchmark Medical, a subsidiary of Kangsheng Global Medical Testing Group, focuses on utilizing tumor DNA methylation sequencing technology for early cancer diagnosis and screening [5] - The company has developed products targeting over 70% of high-incidence cancers, including lung, breast, digestive system, and urinary system cancers, covering the entire process from early screening to diagnosis and monitoring [5] - Benchmark Medical has also created a big data and artificial intelligence platform centered on early screening, diagnosis, and treatment of lung cancer [5]